ITC Seeks Comments on Section 337 Complaint on Antibody Drugs
The International Trade Commission seeks comments by Dec. 1 on a Section 337 complaint alleging that imports of antibody drugs infringe patents held by AbbVie Inc., and ImmunoGen, Inc., it said in a notice to be published Nov. 21 in…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
the Federal Register. According to the complaint, AbbVie is seeking a limited exclusion order and cease and desist orders against ProfoundBio, Genmab and their subsidiaries to bar from entry "certain antibody drug conjugates products and components thereof and products containing the same" that violate their patents. AbbVie said that its product ELAHERE, is "a first-in-class ADC approved to treat adult patients with certain ovarian, fallopian tube, and primary peritoneal cancers."